137 Stock Overview
A biotechnology company, develops and commercializes medicines for immune-mediated diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aldeyra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.92 |
| 52 Week High | US$5.79 |
| 52 Week Low | US$2.15 |
| Beta | 1.43 |
| 11 Month Change | 0.80% |
| 3 Month Change | 51.29% |
| 1 Year Change | 87.53% |
| 33 Year Change | -39.30% |
| 5 Year Change | -10.60% |
| Change since IPO | -0.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 137 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.9% | 0.5% | -1.4% |
| 1Y | 87.5% | -16.2% | 11.8% |
Return vs Industry: 137 exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 137 exceeded the German Market which returned 13.9% over the past year.
Price Volatility
| 137 volatility | |
|---|---|
| 137 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 137's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 137's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 10 | Todd Brady | www.aldeyra.com |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
Aldeyra Therapeutics, Inc. Fundamentals Summary
| 137 fundamental statistics | |
|---|---|
| Market cap | €291.73m |
| Earnings (TTM) | -€35.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.5x
P/E RatioIs 137 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 137 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.87m |
| Earnings | -US$37.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 15.5% |
How did 137 perform over the long term?
See historical performance and comparison